NTRR: Cannabis’ Better-than-Expected Tax Revenues Could Speed Legalization Efforts

LAS VEGAS, NV / ACCESSWIRE / June 8, 2016 / Legalized cannabis has created tax windfalls for Washington and Colorado, and other states currently on the legalization fence are enviously and eagerly eyeing those results. For Neutra Corp. (OTCQB: NTRR), this scenario could create a positive environment for its cannabis-related business as more and more revenue-hungry states approve the substance for adult recreational use to grab additional tax monies.

According to the non-profit Tax Foundation, “A mature marijuana industry could generate up to $28 billion in tax revenues for
federal, state, and local governments, including $7 billion in federal revenue: $5.5 billion from business taxes and $1.5 billion from income and payroll taxes.”

Those projections could prove irresistible to cash-strapped governments looking for painless ways to fund vital programs. Meanwhile, voters are ready to give them the okay. In California, 60 percent of voters support adult-use legalization, according to a recent Probolsky Research poll. More than half of voters in Massachusetts and Michigan also support legalization, studies show.

NTRR is hard at work marketing and promoting new, antimicrobial alternatives to harsh chemicals used in cannabis farms. In 2016, NTRR plans to continue to source out solutions for cannabis producers and consumers alike as the regulated cannabis industry continues to swell in the United States, Canada and beyond. For more information on the company’s mission, please visit neutrainc.com/investors.

About
Neutra Corp.

As the global cannabis market grows exponentially, it is constantly in need of better technologies and products to be more efficient in how they grow, what they grow, and how they consume cannabis and its related products. From lighting to dosage devices, from pesticide replacements to plant enhancers, NTRR is constantly combing the industry for the latest and greatest to test, prove and bring to market.

By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (NASDAQ: GWPH), Cara Therapeutics Inc. (NASDAQ: CARA) and 22nd Century Group, Inc. (NASDAQ: XXII). For investing information and performance data, please visit www.neutrainc.com.

Notice
Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact:

Neutra Corp.
Chris Brown, 813-367-2041
President and CEO
info@neutracorp.com

SOURCE: Neutra Corp.

ReleaseID: 440885